Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States

Bobby Calder, Robert J. Schieffer, Ewa Bryndza Tfaily, Richard Thomas D'Aquila, George J Greene, Alex Carballo-Diéguez, Rebecca Giguere, Patrick Kiser, Thomas J Hope*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Pre-exposure prophylaxis (PrEP) with oral Truvada® prevents HIV infection. However, the adherence to pill taking required for efficacy has sparked interest in developing new antiretroviral delivery systems that decrease such demands. Long-acting formulations, such as injections and implants, represent promising options that require less frequent adherence. It is important, however, that development of these new modalities be driven by understanding of the value seen in them by target users to maximize their uptake. To identify the key product features that impact user acceptance, we used a three-phase marketing research approach. In this study, we describe the results of the first-phase, qualitative focus group research performed in Chicago and San Francisco that explored subjective perceptions of oral versus alternative PrEP modalities among men having sex with men (MSM) and medical practitioners caring for MSM. Data revealed that potential value in long-acting PrEP lies more in simplifying the lives of users rather than in making them more confident in their adherence. The results provide an important guidance for designing and promoting these future long-acting products to enhance their contribution to increasing the current limited uptake of PrEP that will better stem the HIV epidemic.

Original languageEnglish (US)
Pages (from-to)849-856
Number of pages8
JournalAIDS research and human retroviruses
Volume34
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Qualitative Research
San Francisco
Marketing
Focus Groups
Research
HIV Infections
HIV
Injections
Pre-Exposure Prophylaxis

Keywords

  • HIV prevention
  • MSM
  • PrEP
  • adherence

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

@article{10f45ede46fd4023837d514fe0d33034,
title = "Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States",
abstract = "Pre-exposure prophylaxis (PrEP) with oral Truvada{\circledR} prevents HIV infection. However, the adherence to pill taking required for efficacy has sparked interest in developing new antiretroviral delivery systems that decrease such demands. Long-acting formulations, such as injections and implants, represent promising options that require less frequent adherence. It is important, however, that development of these new modalities be driven by understanding of the value seen in them by target users to maximize their uptake. To identify the key product features that impact user acceptance, we used a three-phase marketing research approach. In this study, we describe the results of the first-phase, qualitative focus group research performed in Chicago and San Francisco that explored subjective perceptions of oral versus alternative PrEP modalities among men having sex with men (MSM) and medical practitioners caring for MSM. Data revealed that potential value in long-acting PrEP lies more in simplifying the lives of users rather than in making them more confident in their adherence. The results provide an important guidance for designing and promoting these future long-acting products to enhance their contribution to increasing the current limited uptake of PrEP that will better stem the HIV epidemic.",
keywords = "HIV prevention, MSM, PrEP, adherence",
author = "Bobby Calder and Schieffer, {Robert J.} and {Bryndza Tfaily}, Ewa and D'Aquila, {Richard Thomas} and Greene, {George J} and Alex Carballo-Di{\'e}guez and Rebecca Giguere and Patrick Kiser and Hope, {Thomas J}",
year = "2018",
month = "10",
day = "1",
doi = "10.1089/aid.2018.0214",
language = "English (US)",
volume = "34",
pages = "849--856",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States

AU - Calder, Bobby

AU - Schieffer, Robert J.

AU - Bryndza Tfaily, Ewa

AU - D'Aquila, Richard Thomas

AU - Greene, George J

AU - Carballo-Diéguez, Alex

AU - Giguere, Rebecca

AU - Kiser, Patrick

AU - Hope, Thomas J

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Pre-exposure prophylaxis (PrEP) with oral Truvada® prevents HIV infection. However, the adherence to pill taking required for efficacy has sparked interest in developing new antiretroviral delivery systems that decrease such demands. Long-acting formulations, such as injections and implants, represent promising options that require less frequent adherence. It is important, however, that development of these new modalities be driven by understanding of the value seen in them by target users to maximize their uptake. To identify the key product features that impact user acceptance, we used a three-phase marketing research approach. In this study, we describe the results of the first-phase, qualitative focus group research performed in Chicago and San Francisco that explored subjective perceptions of oral versus alternative PrEP modalities among men having sex with men (MSM) and medical practitioners caring for MSM. Data revealed that potential value in long-acting PrEP lies more in simplifying the lives of users rather than in making them more confident in their adherence. The results provide an important guidance for designing and promoting these future long-acting products to enhance their contribution to increasing the current limited uptake of PrEP that will better stem the HIV epidemic.

AB - Pre-exposure prophylaxis (PrEP) with oral Truvada® prevents HIV infection. However, the adherence to pill taking required for efficacy has sparked interest in developing new antiretroviral delivery systems that decrease such demands. Long-acting formulations, such as injections and implants, represent promising options that require less frequent adherence. It is important, however, that development of these new modalities be driven by understanding of the value seen in them by target users to maximize their uptake. To identify the key product features that impact user acceptance, we used a three-phase marketing research approach. In this study, we describe the results of the first-phase, qualitative focus group research performed in Chicago and San Francisco that explored subjective perceptions of oral versus alternative PrEP modalities among men having sex with men (MSM) and medical practitioners caring for MSM. Data revealed that potential value in long-acting PrEP lies more in simplifying the lives of users rather than in making them more confident in their adherence. The results provide an important guidance for designing and promoting these future long-acting products to enhance their contribution to increasing the current limited uptake of PrEP that will better stem the HIV epidemic.

KW - HIV prevention

KW - MSM

KW - PrEP

KW - adherence

UR - http://www.scopus.com/inward/record.url?scp=85055077779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055077779&partnerID=8YFLogxK

U2 - 10.1089/aid.2018.0214

DO - 10.1089/aid.2018.0214

M3 - Article

VL - 34

SP - 849

EP - 856

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 10

ER -